Over the past year, many tech heavyweights have begun moving into the mHealth sector. Developers got an early look at Google's offering this week, with the search giant releasing a preview version of its APIs for health app developers.
It took GlaxoSmithKline 30 years to get its new malaria vaccine ready for regulatory review. But global health officials--driven by a worldwide clamor--are excitedly pointing to GSK now as one of its prime candidates for getting a vaccine to fight Ebola in a matter of months.
Sanofi has reached out to Seattle biotech Immune Design, looking to borrow the company's drug discovery platform to develop new treatments for food allergies.
Japanese drugmaker Astellas Pharma has teamed up with Cancer Research U.K. to join forces on early-stage oncology R&D, working to identify new treatments for pancreatic cancer.
Google released a preview of its software development kit for fitness apps on Aug. 7. The software will interact with wearable devices and enable a variety of apps to benefit from information about a user's fitness history stored on a centralized interface.
A U.S. research team has made progress toward creating a biomarker blood test that can detect esophageal cancer on the early side, a major need in order to combat the lethal disease.
Over the past year a clutch of startups have talked up their ability to automate aspects of R&D by matching software to robotic technologies. But the ambitions of some groups go well beyond these examples, with researchers aiming to create robo-chemists.
PatientsLikeMe is continuing to expand its business into new areas. Having struck its first broad R&D collaboration with a biopharma earlier this year, the online patient network has now given Actelion access to its community to create a new health outcome measure for a rare cancer.
Wet age-related macular degeneration is the leading cause of blindness in the developed world. The standard of care calls for about 8 costly injections into the eye of medication containing anti-VEGF (vascular endothelial growth factor) per year. "In the real world having patients maintain that level of monitoring and therapy just does not happen," Jim Taylor, who has struggled to convince his aging mother to receive the therapy, told FierceMedicalDevices in an interview.
Regeneron has again dialed up its R&D budget, spending more and more on a slew of late-stage assets that promise to line its pockets and an emerging crop of early drugs the Big Biotech believes can beat a path to blockbuster status.